News Wire
MarketsHere’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4
Vertex Pharmaceuticals (VRTX) saw a strong performance in Q4, primarily driven by robust sales of its cystic fibrosis (CF) drugs. The company's innovative treatments in the CF space continue to demonstrate significant market penetration, contributing to its positive financial results for the quarter.
Related Articles
Diebold Nixdorf Set to Join S&P SmallCap 600
bullish
Yahoo Finance
about 1 hour ago
US Equity Indexes Mixed, Crude Oil Drops as Investors Weigh Pakistan's Ceasefire Plan for Iran
neutral
Yahoo Finance
about 1 hour ago
Dow Jones Futures: Stocks Whipsaw Into Trump's Iran War Deadline; Apple, Tesla Slump
$AAPL
bearish
Yahoo Finance
about 1 hour ago
Private Credit Experiencing 'Growing Pains,' SLR Capital Partners' Co-CEO Gross
bearish
Bloomberg
about 1 hour ago
You May Also Like
Diebold Nixdorf Set to Join S&P SmallCap 600
Yahoo Finance•about 1 hour ago
US Equity Indexes Mixed, Crude Oil Drops as Investors Weigh Pakistan's Ceasefire Plan for Iran
Yahoo Finance•about 1 hour ago
$AAPL
Dow Jones Futures: Stocks Whipsaw Into Trump's Iran War Deadline; Apple, Tesla Slump
Yahoo Finance•about 1 hour ago
Private Credit Experiencing 'Growing Pains,' SLR Capital Partners' Co-CEO Gross
Bloomberg•about 1 hour ago
CrowdStrike, Palo Alto Networks shares pop as cybersecurity bulls finally get some AI validation
MarketWatch•about 1 hour ago
$AAPL
Apple’s stock pares losses. Here’s how to think about the latest saga with foldable iPhones.
MarketWatch•about 1 hour ago